The association of MTHFR C677T gene variants and lipid profiles or body mass index in patients with diabetic and nondiabetic coronary heart disease

Journal of Clinical Laboratory Analysis

Volumn 27, Issue 6, 2013, Pages 427-434

  Kucukhuseyin, Ozlem ^a   Kurnaz, Ozlem ^a   Akadam Teker, A Basak ^a   Isbir, Turgay ^b   Bugra, Zehra ^c   Ozturk, Oguz ^a   Yilmaz Aydogan, Hulya ^a  

^a ISTANBUL UNIVERSITY   (Turkey)

^b YEDITEPE UNIVERSITY   (Turkey)

^c ISTANBUL UNIVERSITY   (Turkey)

Author keywords

BMI; Coronary heart disease; Lipid profiles; MTHFR; Polymorphism

Indexed keywords

ADULT; AGAR GEL ELECTROPHORESIS; ARTICLE; BODY MASS; CONTROLLED STUDY; DIABETES MELLITUS; DIABETIC PATIENT; FEMALE; GENE FREQUENCY; GENETIC ASSOCIATION; GENETIC VARIABILITY; GENOTYPE; HUMAN; HYPERLIPOPROTEINEMIA; ISCHEMIC HEART DISEASE; MAJOR CLINICAL STUDY; MALE; OBESITY; POLYMERASE CHAIN REACTION; RESTRICTION FRAGMENT LENGTH POLYMORPHISM; RISK FACTOR;

BMI; CORONARY HEART DISEASE; LIPID PROFILES; MTHFR; POLYMORPHISM;

ADULT; AGED; BODY MASS INDEX; CORONARY DISEASE; DIABETES COMPLICATIONS; FEMALE; GENETIC ASSOCIATION STUDIES; GENOTYPE; HUMANS; LIPIDS; MALE; METHYLENETETRAHYDROFOLATE REDUCTASE (NADPH2); MIDDLE AGED; OBESITY; POLYMORPHISM, SINGLE NUCLEOTIDE; RISK FACTORS;

EID: 84887335969     PISSN: 08878013     EISSN: 10982825     Source Type: Journal    
DOI: 10.1002/jcla.21623     Document Type: Article

References (42)

1. Novelli G, Borgiani P, Giardina E, et al. Role of genetics in prevention of coronary atherosclerosis. Curr Opin Cardiol 2003;18: 368-71.
2. Hansson GK. Inflammation, atherosclerosis, and coronary artery disease. N Engl J Med 2005;352:1685-1695.
3. Libby P. Inflammation and cardiovascular disease mechanisms. Am J Clin Nutr 2006;83:456S-460S.
4. Yan SF, Ramasamy R, Naka Y, Schmidth AM. Glycation, inflammation, and RAGE: A scaffold for the macrovascular complications of diabetes and beyond. Circ Res 2003;93:1159-1169.
5. Ross R. The pathogenesis of atherosclerosis: A perspective for the 1990s. Nature 1993;362:801-809.
6. Grundy SM. Obesity, metabolic syndrome, and cardiovascular disease. J Clin Endocrinol Metab 2004;89:2595-2600.
7. Weisberg I, Tran P, Christensen B, Sibani S, Rozen R. A second genetic polymorphism in methylenetetrahydrofolate reductase (MTHFR) associated with decreased enzyme activity. Mol Genet Metab 1998;64:169-172.
8. Loktionov A, Vorster H, O'Neill IK, et al. Apolipoprotein E and methylenetetrahydrofolate reductase genetic polymorphism in relation to other risk factors for cardiovascular disease in UK Caucasians and Black South Africans. Atherosclerosis 1999;145: 125-135.
9. Frosst P, Blom HJ, Milos R, et al. A candidate genetic risk factor for vascular disease: A common mutation in methylenetetrahydrofolate reductase. Nat Genet 1995;10:111-113.
10. Kerkeni M, Addad F, Chauffert M, et al. Hyperhomocysteinaemia, methylenetetrahydrofolate reductase polymorphism and risk of coronary artery disease. Ann Clin Biochem 2006;43:200-206.
11. Gil-Prieto R, Hernandez V, Cano B, Oya M, Gil A. Plasma homocysteine in adolescents depends on the interaction between methylenetetrahydrofolate reductase genotype, lipids and folate: A serpepidemiological study. Nutr Metab 2009;6(39):1-9.
12. Khang SS, Wong PWK, Bock HG, Horwitz A, Grix A. Intermediate hyperhomocysteinemia resulting from compound heterozygosity of methylenetetrahydrofolate reductase mutations. Am J Hum Genet 1991;48:546-551.
13. Montalescot G. Homocysteine: The new player in the field of coronary risk. Heart 1996;76:101-102.
14. Boushey CJ, Beresford SA, Omenn GS, Motulsky AG. A quantitative assessment of plasma homocysteine as a risk factor for vascular disease: Probable benefits of increasing folic acid intakes. JAMA 1995;274:1049-1057.
15. McCully KS. Vascular pathology of homocyteinemia: Implications for the pathogenesis for arteriosclerosis. Am J Pathol 1969;56: 111-128.
16. Christen WG, Ajani UQ, Glynn RJ, Hennekens CH. Blood levels of homocysteine and increased risk of Cardiovascular disease. Arch Intern Med 2000;160:422-434.
17. Harker LA, Ross R, Slichter SJ, Scott CR. Homocyteine induced arteriosclerosis: The role of endothelial cell injury and platelet response in its genesis. J Clin Invest 1976;58:731-741.
18. Tsai JC, Perella MA, Yoshizumi M, et al. Promotion of vascular smooth muscle cell growth by homocysteine: A link to atherosclerosis. Proc Natl Acad Sci USA 1994;91:6369-6373.
19. Huang T, Yuan G, Zhang Z, Zou Z, Li D. Cardiovascular pathogenesis in hyperhomocysteinemia. Asia Pac J Clin Nutr 2008;17:8-16.
20. Rothenbacher D, Fischer HG, Hoffmeister A, et al. Homocysteine and methylenetetrahydrofolate reductase genotype: Association with risk of coronary heart disease and relation to inflammatory, hemostatic, and lipid parameters. Atherosclerosis 2002;162: 193-200.
21. Bailey LB, Gregory JF. Polymorphisms of methylenetetrahydrofolate reductase and other enzymes: Metabolic significance, risks and impact on folate requirement. J Nutr 1999;129:919-22.
22. Koo HS, Lee HS, Hong YM. Methylenetetrahydrofolate reductase TT genotype as a predictor of cardiovascular risk in hypertensive adolescents. Pediatr Cardiol 2008;29:136-141.
23. Bjorck J, Hellgren M, Rastam L, Lindblad U. Associations between serum insulin and homocysteine in a Swedish population-A potential link between the metabolic syndrome and hyperhomocysteinemia: The Skaraborg project. Metabolism 2006;55:1007-1013.
24. Schachter M, Raziel A, Friedler S, Strassburger D, Bern O, Ron-EI R. Insulin resistance in patients with polycystic ovary syndrome is associated with elevated homocysteine. Hum Reprod 2003;18: 721-727.
25. Jacques PF, Bostom AG, Wilson PW, Rich S, Rosenberg IH, Selhub J. Determinants of plasma total homocysteine concentration in the Framingham offspring cohort. Am J Clin Nutr 2001;73:613-621.
26. Koehler KM, Romero LJ, Stauber PM, Pareo-Tubbeh SL, Liang HC. Vitamin supplementation and other variables affecting serum homocysteine and methylmalonic acid concentrations in elderly men and women. J Am Coll Nutr 1996;15:364-376.
27. Miller SA, Dykes DD, Polesky HF. A simple salting out procedure for extracting DNA from human nucleated cells. Nucleic Acids Res 1998;6:1215.
28. Qujed D, Omran TS, Hosini L. Correlation between total homocysteine, low-density lipoprotein cholesterol and high-density lipoprotein cholesterol in the serum of patients with myocardial infarction. Clin Biochem 2001;34:97-101.
29. Kluijtmans LAJ, Van den Heuvel LPWJ, Boers GHJ, et al. Molecular genetic analysis in mild hyperhomocysteinemia: A common mutation in methylenetetrahydrofolate reductase gene is a genetic risk factor for cardiovascular disease. Am J Hum Genet 1996;58:35-41.
30. Falchi A, Giovannoni L, Piras IS, et al. Prevalence of genetic risk factors for coronary artery disease in Corsica island (France). Exp Mol Pathol 2005;79:210-213.
31. Schmitz C, Lindpaintner K, Verhoef P, Gaziano JM, Buring J. Genetic polymorphism of methylenetetrahydrofolate reductase and myocardial infarction: A case-control study. Circulation 1996;94:1812-1814.
32. Ma J, Stampfer MJ, Hennekens CH, et al. Methylenetetrahydrofolate reductase polymorphism, plasma folate, homocysteine, and risk of myocardial infarction in US physicians. Circulation 1996;94:2410-2416.
33. Wilcken DEL, Wang XL, Sim AS, McCredie RM. Distribution in healthy and coronary populations of the methylenetetrahydrofolate reductase (MTHFR) C677T mutation. Arterioscler Thromb Vasc Biol 1996;16:878-882.
34. Botto LD, Yang Q. 5, 10-Methylenetetrahyrofolate reductase gene variants and congenital anomalies: A HuGE review. Am J Epidemiol 2000;151:862-877.
35. Sadewa AH, Sunarti SR, Hayashi C, et al. The C677T mutation in the methylenetetrahydrofolate reductase among the Indonesian Javanese population. Kobe J Med Sci 2002;48:137-144.
36. Jacques PF, Bostom AG, Williams RR, et al. Relation between folate status, a common mutation in methylenetetrahydrofolate reductase, and plasma homocysteine concentrations. Circulation 1996;93:7-9.
37. Verhoef P, Stampfer MJ, Buring JE, et al. Homocysteine metabolism and risk of myocardial infarction: Relation with vitamins B6, B12, and folate. Am J Epidemiol 1996;143:845-859.
38. Selhub J, Jacques PF, Wilson PW, Rush D, Rosenberg IH. Vitamin status and intake as primary determinants of homocysteinemia in an elderly population. J Am Med Assoc 1993;270:2693-2698.
39. Huang T, Tucher KL, Lee YC, et al. Methylenetetrahydrofolate reductase variants associated with hypertension and cardiovascular disease interact with dietary polyunsaturated fatty acids to modulate plasma homocysteine in Puerto Rican adults. J Nutr 2011;141:654-659.
40. Böger CA, Stubanus M, Haak T, et al. Effect of MTHFR C677T genotype on survival in type 2 diabetes patients with end-stage diabetic nephropathy. Nephrol Dial Transplant 2007;22: 154-162.
41. Bar-On H, Kidron M, Friedlander Y, et al. Plasma total homocysteine levels in subjects with hyper insulinemia. J Intern Med 2000;247:287-294.
42. Chango A, Boisson F, Barbé F, et al. The effect of 677C → T and 1298A → C mutations on plasma homocysteine and 5, 10methylenetetrahydrofolate reductase activity in healthy subjects. Br J Nutr 2000;83:593-596.